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Abstract 
 
Background 
Cardiac surgery is associated with perioperative bleeding which may result in the 
need for blood transfusion, particularly in paediatric congenital cardiac surgery 
performed on cardiopulmonary bypass (CPB). Regular auditing of practices is 
imperative for improvements to be realised.  
Methods 
Retrospective, contextual, descriptive data of 105 patients were collected for the 
period January to December 2014.  
Results 
The median age of patients was 4 (1–6) years, weight 13 (8.4–20) kg, with mean 
lowest CPB haemoglobin of 8.3 (1.5) g/dL. There was a statistically significant 
difference in median red packed cells (RPC), platelet and cryoprecipitate units 
transfused per patient across Risk Adjusted classification for Congenital Heart 
Surgery categories (p=0.03, p=0.0013, p=0.0001). There was a statistically 
significant correlation between transfused fresh frozen plasma units with CPB time 
(r=0.2634, p=0.0199) and RPC units transfused (r=-0.4654, p<0.001).  
Conclusion 
Although no standardised transfusion guidelines were available, overall blood 
product transfusion was comparable to previous reports. 
1 
 
SECTION 1 
Literature Review 
 
1.1   Introduction 
This literature review will start with a brief history of blood transfusion, and cardiac 
surgery in paediatric patients. A discussion of the different blood products, and 
factors contributing to the transfusion of blood products during paediatric cardiac 
surgery will be discussed. The complications related to blood product transfusion, 
and the guidelines to transfuse blood products during paediatric cardiac surgery will 
be explored. A discussion on blood conservation strategies, the benefits of the 
implementation of these strategies, and the cost implications of blood product 
transfusion will also be discussed. A review of practices by other institutions with 
regards to utilisation of blood products will be reviewed. 
1.2   Brief history of blood transfusion and paediatric cardiac 
surgery 
The history of blood transfusion goes as far back as the discovery of the circulatory 
system in 1616. Blood transfusion evolved from drinking of blood by Pope Innocent 
VIII, although not considered a true transfusion, to transfusion of a dog by Richard 
Lower, in 1665. This was followed by the first transfusion of man by Denis in 1667, 
and the discovery of an incompatibility reaction. Carl Landsteiner, in 1900, described 
the existence of three blood groups. The first blood bank was subsequently 
established in 1934 at the Cook Country Hospital, in Chicago. (1) 
The first paediatric cardiac operation was performed by Clarence Crafoord in 
Sweden. He repaired a coarctation of the aorta in a 12 year old boy on 19 October 
1944 (2), this was before development of the cardiopulmonary (CPB) machine 
where. Russell M. Nelson performed the first successful paediatric cardiac operation 
on CPB at the Salt Lake General Hospital in March 1956. He performed a total repair 
of tetralogy of Fallot on a four year old girl (3).   
The evolution and development of blood products and CPB machines has made it 
possible for surgeons to operate on complex cardiac conditions with great success. 
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1.3   Blood products 
The use of blood products has become common practice for health care workers. 
Red packed cells (RPC), platelets, fresh frozen plasma (FFP), and cryoprecipitate 
are the commonly used blood products in paediatric cardiac surgery, and will be 
briefly discussed. 
1.3.1 Red packed cells 
RPC are concentrated red blood cells collected after removal of plasma, platelets, 
and leucocytes (buffy layer) from whole blood. The concentrated red blood cells 
collected have a haematocrit (Hct) level of 70 to 80% which is reduced to a Hct of 
55% by the addition of normal saline and preservatives. The added preservatives 
include adenine for generation of ATP, glucose for energy, citrate to prevent clotting, 
saline, and mannitol to maintain cell integrity during the storage period. RPC can be 
stored for 42 days at 1 to 6 °C (4, 5). The recommended dosing for RPC in paediatric 
patients less than four months is 10 to 20 ml/kg, and above four months it is 
calculated according to the equation:  
Dose (mL)= desired haemoglobin (Hb) rise (g/dL) x weight (kg) x3. (6) 
The use of leucocyte depleted RPC is recommended in children less than one year 
of age (6). Leucocytes have been implicated in immunomodulation, transmission of 
cytomegalovirus (6), and the initiation of an inflammatory response which is 
worsened by the use of CPB (7). 
1.3.2 Platelets 
Platelets are fragments of cytoplasm formed from megakaryocytes and have a 
biconvex discoid shape with a diameter of 2 to 3 µm (4). They are used to prevent or 
treat bleeding disorders that might be due to thrombocytopenia or decreased function 
of platelets (5). 
Platelets are collected by the centrifugation of whole blood within eight hours of 
collection, and are then kept viable by continuous agitation to ensure oxygenation 
and prevent clumping. They are stored at room temperature for five days as this is 
their life span outside the body (4, 5). The transfusion dose of platelets is 5-10 ml/kg 
in neonates and 10 to 20 ml/kg in infants (6). 
1.3.3 Fresh frozen plasma 
FFP is plasma collected from whole blood by centrifugation and separation, then 
frozen within eight hours of collection and stored at -18 °C. The plasma consists of 
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normal volume of all clotting proteins, albumin, immunoglobulins, and 70% of plasma 
factor VIII as a dilute solution of 200 to 250 ml. The FFP must be thawed before 
usage at 36 °C to defrost (4, 5). It is usually infused when there is coagulation factor 
deficiency, to reverse anticoagulation, and during massive bleeding at a dose of 10-
15 ml/kg (8). 
1.3.4 Cryoprecipitate 
Cryoprecipitate is a precipitate of thawed plasma consisting of concentrated clotting 
proteins. The clotting proteins are fibrinogen, fibronectin, von Willebrand factor, factor 
V, factor VIII, and factor XIII in a volume of 15-20 ml (4, 9). It is transfused during 
massive transfusion, or when there is fibrinogen deficiency. The recommended 
transfusion dose is 5 ml/kg for neonates (6), and one unit per 5-10 kg for infants and 
children (8).  
1.4   Factors that influence blood products transfusion in paediatric 
cardiac surgery 
Indications for transfusion of blood products in the paediatric cardiac patient are 
multifactorial. Factors that will be discussed are type of congenital cardiac condition, 
age, weight of the patient and CPB related factors. 
1.4.1 Congenital cardiac conditions 
Corrective surgery for congenital cardiac conditions is categorised by the Risk 
Adjusted classification for Congenital Heart Surgery (RACHS) scoring system. Each 
category signifies the complexity of the operation as the category number increases, 
and is associated with increasing risk of bleeding (10).  
Congenital cardiac conditions are associated with activation of the coagulation 
cascade secondary to shear stress from turbulent flow of blood (11), resulting in a 
decrease in platelet count and consumption of clotting factors (12). These 
abnormalities are more pronounced in cyanotic cardiac conditions, hence the focus 
on studying other mechanisms causing coagulopathy (12). 
Patients with cyanotic cardiac conditions are at an increased risk of bleeding 
because of the acquired haemostatic disorder (13) as a result of chronic hypoxaemia. 
The chronic hypoxaemia and hypoxia stimulates the release of erythropoietin by the 
kidneys, resulting in erythrocytosis (11). This secondary erythrocytosis leads to blood 
hyperviscosity which causes shear stress activating platelets and resulting in 
thrombocytopenia and an increase in number of micro particles (14, 15). The 
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secondary erythrocytosis has also been implicated in causing fibrinogen dysfunction 
(16). These abnormalities could be the reason for the increased risk in postoperative 
bleeding in cyanotic infants when compared to the acyanotic patients (17). 
Other causes of thrombocytopenia in cyanotic patients is underproduction of platelets 
as a result of erythrocytosis in the fixed intravascular volume (13), and failure of 
fragmentation of megakaryocytes as they bypass the lungs (15). There is an 
associated decrease in cardiac output, liver congestion and liver dysfunction as a 
result of hypoxaemia. The liver dysfunction causes a decrease in liver production of 
clotting factors, especially vitamin K dependent factors (factor II, V, VII, IX, X) 
contributing to the coagulopathy (11). 
1.4.2 Age and weight of child 
Neonates have an immature hepatic system resulting in reduced function of clotting 
factor production predisposing them to bleeding. Adult levels of clotting factors are 
only reached  between 6 to 12 months of age (18). Neonates might have a normal  
platelet count, but their function is decreased until 2 to 4 weeks after birth (19). This 
becomes a problem when the patient is younger than 12 months, and has to be on 
CPB, as CPB is associated with coagulopathy secondary to haemodilution (18, 20). 
Kipps et al (21) conducted a study demonstrating that young age, lower weight at 
surgery, and prematurity are associated with increased risk for blood product 
transfusion.   
1.4.3 Cardiopulmonary bypass 
CPB is a none physiological system (18) that is used to temporarily take over the 
function of the heart and lungs during open cardiac surgery. Heparin must be given 
to the patient before initiation of the CPB machine to prevent thrombosis. This 
thrombosis is caused by blood contact with the CPB circuit resulting in contact 
activation of thrombin and clotting factors, which initiates the coagulation cascade. 
This results in consumption of clotting factors predisposing to bleeding (22). 
CPB is associated with impairment of haemostasis due to the dilution of the patients 
(Hb), clotting factors (18), platelet, and fibrinogen levels (17). The dilution is 
exaggerated in the paediatric population due to their small total blood volume relative 
to the CPB machine, hence the use of FFP prime in neonates (17). Priming the CPB 
circuit with RPC is perfomed to obtain the desired Hb on CPB (23).  
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In order to attenuate the haemodilution caused by CPB circuit prime, priming with 
RPC and FFP is commonly practiced in paediatric congenital cardiac surgery on CPB 
(24-26). However, studies conducted to compare priming with colloid to FFP, found 
no difference in risk of bleeding between the groups (13, 27, 28).  A study in 
neonates and infants, in contrast, demonstrated reduced bleeding in patients with 
FFP when compared to albumin prime, due to preservation of fibrinogen level (29). 
The risk of transfusion of blood products is increased in complex and emergency 
operations, and in very young patients with a low preoperative red blood cell volume 
(9, 30). The risk is also increased by prolonged aortic cross clamp and CPB time (21, 
31, 32) .  
1.5   Complications of blood product transfusion  
Transfusion of blood products is a common practice in the hospital and it is important 
to know its complications in order to obtain informed patient consent and detect 
adverse effects early if they arise. The South African National Blood Service 
(SANBS) has adopted a haemovigilance programme since 2001. This programme 
consists of processes intended to improve quality, and safety of transfused blood 
products by using appropriate screening tests, and monitoring the blood transfusion 
chain from donor to recipient. The monitoring process includes risk management, 
reporting of adverse transfusion reactions, and auditing blood product usage to see 
whether blood products are transfused following guidelines or wasted (33, 34). 
Complications associated with transfusion of blood products are discussed below. 
1.5.1 General complications of blood transfusion 
The most common complication of transfusion of blood products is due to human 
errors, which are as high as 77% according to the 2016 Serious Hazards of 
Transfusion Report (35). These errors are preventable by taking precautions during 
blood specimen handling. It requires the collection of the blood specimen into an 
appropriate tube which is correctly labelled, and proper handling by the blood bank 
personnel. The health care workers should also recheck the patient’s details with the 
issued unit before the transfusion of the blood product unit is initiated. The infectious 
and non-infectious complications as well as the CBP related complications are shown 
in Table 1.1. 
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1.5.2 Infectious 
In South Africa, the incidence of transfusion transmitted infection is minimal (Table 
1.1) from the statistics by the SANBS 2007. The reason for the low incidence for 
transfusion transmitted infections might be because of the introduction of nucleic acid 
amplification testing, since 2005, by SANBS, and failure to follow and report cases by 
health care workers (36). The risk of infection increases with the amount of products 
transfused during the operation (21), this could also be due to immunomodulation 
ensuing in immunosuppression. 
Table 1.1 SANBS reported incidence of infection and infectious agents (34) 
Infectious agent Period Incidence  
Virus 
HIV 2001 to 2007 6 cases reported 
Hepatitis B 2005 to 2007 Donor prevalence of 0.077 
Hepatitis C 2005 to 2007 Donor prevalence of 0.0062 
Bacteria 
RPC 2000 to 2007 7 cases 
Platelets Apheresis 2007 7/530 cases tested positive 
Parasites 
Malaria 2007 No cases reported 
 
1.5.3 Non-infectious 
Non-infectious blood product transfusion complications are problematic because they 
are not preventable. These complications are solely dependent on the patient’s 
immune system response. 
The haemolytic transfusion reaction is preceded by antibody-antigen incompatibility 
in plasma during the transfusion of blood products. This complication can occur 
within minutes to 24 hours (early), or 2 to 21 days (delayed) post transfusion of blood 
products. The early reaction occurs due to ABO incompatibility or alloantibodies 
causing intravascular haemolysis and the destruction of transfused or recipient blood. 
The delayed reaction is caused by incompatibility of rare blood groups, for example 
Rhesus and Kidd, resulting in extravascular haemolysis (5). The allo-immunisation 
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caused by transfusion of blood products can result in acute lung injury, haemolytic 
reactions, transplant rejection, and allo-immune thrombocytopenia (37). 
The non-haemolytic reaction is due to sensitisation of the patient’s immune system to 
donated white cells, platelets or plasma proteins (5). The manifestations ranges from 
a simple allergic reaction mediated by immunoglobulin E to an anaphylactic reaction 
commonly seen in immunoglobulin A deficient patients when blood products having 
anti-immunoglobulin A antibodies are transfused (38). 
The most complex non-haemolytic reaction is post transfusion purpura which is 
caused by developed platelet alloantibodies attacking the patient’s platelets resulting 
in thrombocytopenia (5).  
Graft versus host disease is a rare and delayed transfusion reaction caused by donor 
lymphocytic cells mounting an immune response against the immunocompromised 
host tissue (38). 
Massive transfusion in paediatric patients is defined as a transfusion of greater than 
40 ml/kg (39) or replacement of the patient’s blood volume within six hours (6). 
Ranucci et al (40) states that the small paediatric patient is prone to massive 
transfusion due to their small blood volumes. The sole transfusion of RPC causes 
consumption of platelets and clotting factors which results in dilution coagulopathy 
leading to disseminated intravascular coagulopathy. This coagulopathy is worsened 
by hypothermia caused by infusing cold blood products resulting in an unfavourable 
environment for normal functioning of clotting enzymes (38). 
Massive RPC transfusion can result in citrate toxicity causing hypocalcaemia, and 
hypomagnesaemia due to chelation with citrate which produces myocardial 
suppression and coagulopathy.  The metabolic derangement caused by citrate (38) 
can result in electrolyte abnormalities (8) further compromising cardiovascular 
function. 
Stored RPCs are at different stages of aging. Aged blood has a decrease in 2,3 
diphosphoglycerate resulting in a left shift of the oxygen dissociation curve causing 
poor oxygenation of tissues, and is also associated with renal and pulmonary 
morbidities (40). There is hyperkalaemia caused by potassium leak from stored RPC 
due to none functional Na+-K+ ATPase pump from ATP deficiency (38). 
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1.5.4 Cardiopulmonary bypass related complications 
The inflammatory response in paediatric cardiac surgery on CPB is multifactorial. It is 
caused by the stress response to cardiac surgery, contact of patient blood with the 
CPB circuit, and transfusion of blood products. The response may result in multiple 
organ dysfunction depending on the severity (41). 
Cardiac surgery results in an inflammatory response due to the body’s humoral and 
cellular response to injury (42, 43). Contact of blood with the CPB circuit causes 
cytokine production and activation of neutrophils, platelets and the complement 
system (22). This response is worse in children because their small blood volume is 
exposed to a relatively large CPB circuit surface (41, 44).   
Another source of this inflammatory response occurs after releasing of the aortic 
cross clamp; the reperfusion of previously ischaemic tissues discharges endotoxins 
and cytokine systematically (42). This results in endothelial activation, evidenced by 
release of intracellular lysosomes’ granular contents and the generation of oxygen 
free radicals, causing ventilation perfusion mismatch and endothelial injury (42). The 
endothelial injury causes vasoplegia which leads to haemodynamic instability, 
resulting in further transfusion of blood products, and increased use of inotropes (45). 
The inflammatory response increases capillary permeability resulting in fluid leak into 
the interstitial space causing pulmonary oedema (41). Studies have shown prolonged 
postoperative mechanical ventilation (21, 31, 46), acute kidney injury, and infection 
(31) with increased transfusion of blood products. 
1.6   Transfusion triggers in paediatric cardiac surgery 
Cardiac surgery is associated with perioperative bleeding which may result in the 
need to transfuse, more so if the patient is on CPB. The Society of Thoracic 
Surgeons and the Society of Cardiovascular Anaesthesiologist Blood Conservation 
Clinical Practice Guidelines recommend RPC transfusion in adult patients on CPB for 
cardiac surgery when Hb drops below 6 g/dL in stable patients and to maintain Hb 
above 7 g/dL in patients at risk of end organ ischaemia or injury (9). Transfusion 
guidelines for paediatric patients could not be identified. The transfusion of blood 
products in paediatric patients has been noted to be guided by the patient’s clinical 
condition depending on the cardiac lesion, haemodynamic status, laboratory 
parameters (9), and age (43). 
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Roseff et al (47) suggested RPC transfusion for cyanotic children less than four 
months when Hct is below 45%. In children greater than four months RPC is 
transfused if blood loss exceeds 15% of the patient’s blood volume or Hct is less than 
40% in patients with severe pulmonary disease. These guidelines are stated “to be 
representing the opinions of the authors and incorporating evidenced-based data 
when it exists”, so its validity is not conclusive.  
Table 1.2 shows CPB Hb transfusion trigger, minimal prime volume and conservation 
strategies used in a variety of paediatric studies. 
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Table 1.2  Cardiopulmonary bypass parameters per study 
Study Trigger Hb/ Hct on 
CPB (g/dl/%) 
Minimum prime (ml) Conservation 
strategy 
Friesen 1993 (48) Hb 5 450 MUF 
Chauhan 2004 (49) Hct 24 400  
Miyaji 2007 (45) Hct 20  140 MUF, CS 
Wypij 2007 (50) Hct 20 unknown Mini CPB, MUF 
Durandy 2007 (24) Hb 8  140  Mini CPB 
Szekely 2009 (32) Hct 20 Not stated Antif 
Shimizu 2011 (51) Hct 25 400  
Durandy 2010 (30) Hb 8,  
Hb 10 cyanotic   
100  MUF 
Golab 2011 (52) Hct 28 300  CS 
Hasegawa 2014 (23) Hct 20 Not stated 
 
Mini CPB, Antif, 
MUF 
Supplements  
Romlin 2014 (53) Hct 25 350 MUF, Antif  
Agarwal 2014 (26) 
 
Hct 30 single 
ventricle 
Hct 25 double 
ventricle 
600 
  
CS, UF 
Antif 
Sang Yoon 2015 
(54)  
Hct 28 115  
Guzzetta 2015 (55) Hct 30 250  MUF 
Lin 2015 (56) Hb 10 acyanotic  
Hb 14 cyanotic 
Not stated Antif 
Jobes 2015 (57)  Hct 25 300 
4.4 
MUF 
* Hb-haemoglobin; Hct-haematocrit; MUF-modified ultrafiltration; UF-ultrafiltration; CS-cell saver; Antif-
antifibrinolytic 
1.6.1 Use of transfusion triggers 
Bharadwaj et al (8) and Guzzetta et al (58) supported what The Society of Thoracic 
Surgeons and the Society of Cardiovascular Anaesthesiologists Blood Conservation 
Clinical Practice Guidelines stated about Hb not being the sole trigger for RPC 
transfusion. Other transfusion triggers might be the general condition and 
physiological signs. The majority of studies reviewed in Table 1.2 (23, 24, 32, 45, 49, 
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50, 59, 60) maintained Hb between 7 to 8 g/dL in their paediatric cardiac patients on 
CPB.  
A randomised controlled trial in infant heart surgery on CPB by Wypij et al (50) 
showed unfavourable outcomes in patient with a Hct below 20% as compared to 25% 
and 30%. The morbidities included a positive fluid balance and impaired 
psychomotor development index score after a year. On the contrary, no 
neurodevelopment impairment was observed in older patients (23) and infants (45) 
with a Hct below 20% presenting for low risk cardiac conditions. 
A randomised paediatric ICU study by Cholette et al (61), in  2011, showed that a Hb 
of  9 g/dL can be tolerated by the cyanotic patient. A study by de Gast-Bakker et al 
(62), in 2013, demonstrated that in acyanotic patients, a Hb of 8 g/dL was associated 
with a decreased length of hospital stay.  Another randomised intensive care unit 
study by Lacroix et al (63) showed no difference in nosocomial infection, duration of 
ventilation, duration of ICU stay, and reactions to RPC transfusion between the 
restricted Hb group (7 g/dL) when compared to the liberal group (9,5 g/dL). They 
suggested not employing restrictive Hb strategies in preterm neonates, children with 
severe hypoxaemia, actively bleeding, and haemodynamically unstable or cyanotic 
patients. 
1.7   Blood conservation strategies 
Blood conservation strategies are employed to decrease allogenic blood transfusion 
and include the use of autologous blood transfusion, antifibrinolytic agents, miniature 
CPB, modified ultrafiltration, personnel related factors, point of care tests, and cell 
salvage. 
1.7.1 Preoperative autologous donation 
Preoperative autologous donation is donation of blood by the patient preoperatively 
for use intraoperatively to avoid use of homologous blood as this has unwanted 
adverse effects. It is not feasible in emergency surgery (64) as it requires time to 
collect enough blood to use intraoperatively. Some studies seem to exclude children 
who weigh less than five kg and patients undergoing complex cardiac surgery and 
low Hb (64-67).  
The patient presents to hospital a couple of weeks before the planned operation, and 
weekly 10 ml/kg of blood is collected from the patient, and stored until the operation 
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day. This practice is labour intense as it requires the cooperation and commitment of 
the patient, family and health care workers (65, 66). 
These patients need to be given iron and/or erythropoietin to help regenerate the 
donated blood (7, 23, 64, 65, 67). Although erythropoietin is associated with 
thrombotic and hypertensive events, the only complication noted was an increase in 
platelet count (66). 
Hibino et al (65) showed a decrease in allogeneic blood transfusion in paediatric 
surgery in the preoperative autologous blood donation group when compared to the 
control group. A study by Fu et al (68) showed a decrease in blood transfusion 
requirement in the group which received retrograde autologous prime. The study was 
conducted in patients between 15 to 20 kg and only 3,4% (2/59) had complex cardiac 
conditions. 
1.7.2 Antifibrinolytics agents 
Antifibrinolytic agents are amino acids which impair conversion of plasminogen to 
plasmin and prevent binding of plasmin to fibrinogen and fibrin so that the clot is not 
degraded. They impair platelet aggregation by altering its membranes and kallikrein-
kinin system (4).  
Aprotinin was the most commonly used antifibrinolytic agent in cardiac surgery until 
its withdrawal in 2007 due to concerns of increased kidney damage, cardiac failure, 
thrombosis, and mortality (56). Current practice has moved to the use of tranexamic 
acid (TXA) or epsilon aminocaproic acid which is 10 times less potent than 
tranexamic acid. Studies have shown no difference in effectiveness in a comparison 
between aprotinin and TXA (69, 70), and between TXA and epsilon aminocaproic 
acid (49) in decreasing  blood loss, although there are potency differences between 
the agents. A decrease in RPC transfusion in patients with congenital heart disease 
has been demonstrated with the use of antifibrinolytic agents (23, 49, 69-71). No 
difference was seen in the transfusion of FFP and platelets with the administration of 
antifibrinolytic agents, and the reason for this was not investigated (71). 
The use of antifibrinolytic agents showed a decrease in morbidity when bloodless 
surgery was achieved(23), probably due to the avoidance of immunomodulation 
associated with blood product transfusion. These agents can be used for cyanotic 
and acyanotic cardiac surgery with similar outcomes (51). The effective dose of 
antifibrinolytic agents on CPB is unknown, but it is recommended to give an initial 
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bolus dose of TXA is 20 mg/kg intravenously followed by an infusion at 10 mg/kg/h 
(8). Different institutions have different dosing protocols as noted in the following 
studies: Machovec et al (72) used TXA 75 mg/kg bolus then an infusion of 75 
mg/kg/h on pump;  Hasegawa et al (23) used TXA 100 mg bolus then an infusion at 
10 mg/kg/h; Giordano et al (71) TXA 20 mg/kg at induction and repeated post CPB; 
and Chauhan et al (49) administered aminocaproic acid 100 mg/kg or TXA 10 mg/kg 
three times during the operation. 
1.7.3 Miniature CPB 
Miniature CPB utilises vacuum assisted venous drainage instead of gravity assisted 
drainage (59). Small sized oxygenators with integrated arterial filters, short circuits 
are used, and certain components are omitted to minimise the extent of 
haemodilution (73). A retrospective audit by Golab et al (74) assessing CPB circuit 
size between 1997 and 2008, showed that decreasing the CPB circuit size resulted in 
decreased blood transfusion. Studies have been conducted demonstrating a 
decrease in blood transfusion with the use of miniature CPB in both paediatric (24, 
54) and adult patients (73, 75).  
Miyaji et al (45) conducted a retrospective cohort study on infants undergoing cardiac 
surgery which showed that minimising CPB circuit volume to 140 ml resulted in 64% 
of patients not receiving blood transfusion. Miniature CPB has made it possible to 
conduct bloodless cardiac surgery in paediatric patients. 
1.7.4 Cell salvage  
Cell salvaging is a process involving the collection of blood, mixing it with an 
anticoagulant, washing and centrifuging it, and finally reinfusing it back to the patient 
(76-78). The indications for use of the cell saver are: expectations of bleeding of 
more than 20% of the blood volume (77, 78); multiple antibodies or a rare blood 
types; and refusal of allogeneic blood transfusion (78). It has been used successfully 
in patients weighing less than 10 kg (79).  
The use of a cell saver has resulted in reduced exposure to allogeneic RPC 
transfusion (80). There is better oxygen carrying capacity and tissue oxygenation due 
to the maintainance of 2, 3 diphosphoglycerate concentrations in the salvaged blood 
(77, 78).  The problem with cell salvaging is the shear stress caused by suctioning 
which results in haemolysis. This can be reduced by applying low suction pressures. 
Cell salvaging can lead to coagulopathy due to off of washing of platelets, and 
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clotting factors (78). The safe time duration for storage of salvaged blood to avoid 
contamination is unknown (78, 80). 
1.7.5 Modified ultrafiltration 
Modified ultrafiltration is a process of removing residual fluid from the CPB circuit  
resulting in conservation of red blood cells, plasma proteins and platelets during CPB 
discontinuation (48). The blood collected by modified ultrafiltration has concentrated  
Hb, platelets, albumin, and clotting factors (81). This technique has proven to be 
effective in reducing inflammatory mediators (43, 82) improving pulmonary function 
(82) and total body fluid volume postoperatively (83). 
A prospective study in children by Friesen et al (48) showed a decrease in blood 
transfusion postoperatively with the use of modified ultrafiltration, and similar findings 
were observed in a prospective control trial in adults by Gunaydin et al (81).  
1.7.6 Personnel related factors 
Prolonged operation time in complex procedures increases the risk of bleeding. Kiran 
et al (77) advices that senior surgeons operate complex cases to attain “bloodless 
surgery”. The maintenance of haemostasis by surgeons intraoperatively and short 
operation time reduces the amount of blood lost (84).   
1.8   Point of care tests 
Thromboelastography is one of the tests used to assess the coagulation status of 
whole blood under low shear stress. It requires 0.36 ml of blood poured into a cup 
with a suspended rotating pin. The pin rotates and the degree of rotation is affected 
by the elasticity and clot strength produced. These changes are transmitted via a 
torsion wire to a transducer within the machine which eventually displays results as a 
graph. This is a relatively quick bedside test requiring minimal blood as a sample 
from the patient as compared to a standard clotting test which must be done in the 
laboratory (85). 
Although small sized, a prospective study by Wagner et al (86) suggests using 
rotational thromboelastometry to access bleeding tendencies in cardiac surgery. A 
retrospective randomised control study by Kane et al (25) demonstrated a significant 
reduction in platelet and cryoprecipitate transfusion during paediatric congenital 
surgery using a thromboelastogram device. This resulted in guided transfusion of 
blood products. The study explains the lack of impact of the thromboelastogram on 
RPC and FFP transfusion when these products are used to prime the CPB circuit. 
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An activated clotting time is displayed once heparinised whole blood is processed. In 
comparison, the haemostasis management system gives the heparin dose response 
curve, activated clotting time, heparin concentration, and protamine dose needed to 
reverse the heparin (87) . The haemostasis management systems is a better bedside 
test to assess coagulopathy than activated clotting time as it gives more information 
than just a single value (88). A cohort study by Machovec et al (89) showed a 
decreased transfusion exposure with the use of the haemostasis management 
system compared to activated clotting time. The disadvantage of using activated 
clotting test in infants is that it is prolonged by antithrombin deficiency, hypothermia 
and haemodilution (11, 88).  
1.9   Benefits of conservation strategies 
Bloodless surgery can be achievable as evidenced by the studies in Table 1.3. 
Paediatric Jehovah’s Witness patients have had bloodless corrective cardiac surgery 
on CPB with good outcomes. Bloodless surgery was possible in 29% (76/259) of 
patients in a study by Durandy et al (24) as a result of utilisation of blood 
conservation strategies. 
Table 1.3 Bloodless surgeries with associated strategies 
Study  Procedure Prime/Min Hb Strategy  
Carmichael et 
al (52)  
 Variable  500 ml 
Hb 5.5 g/dL 
None  
Hubler et al 
(90) 
TAPVD repair 190 ml 
Hb 8 g/dL 
Aprotinin 
CS, miniature CPB 
Hasegawa et 
al (23)  
ASD, VSD 
repair 
450 ml 
Hct 20% 
Supplement, erythropoietin, TXA, 
UF, miniature CPB, ABD, CS 
Ratliff et al (91) Ventricle to 
aorta tunnel 
repair, AVR 
176 ml 
Hb 6.1 g/dL 
Miniature CPB, UF, CS, TXA, ABD 
Boettcher et al 
(92) 
AVSD, TGV 43 ml 
Hb 10 g/dl 
Miniature CPB 
*TAPVD-total anomalous pulmonary venous disease; VSD-ventricular septal defect; ASD-atrial septal defect; AVR-aortic valve 
replacement; AVSD-atrioventricular septal defect; TGV-transposition of great vessels; MUF-modified ultrafiltration, CS-cell 
saver; ABD-autologous blood donation; Hct-haematocrit ; Hb-haemoglobin; CPB-cardiopulmonary bypass 
1.10 Cost implications of blood transfusions 
Blood products are expensive and use in paediatric cardiac surgery is an almost 
unavoidable practice. According to the SANBS price list, more processing which is 
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necessary in the production paediatric patients bold products lead to more expense 
(93).  
There is an increase in the number of blood products transfused compared to the 
number of donors presenting for blood pooling (9) which shows the scarceness of 
blood products. A study conducted in Saudi Arabia revealed that a lack of blood 
products was one of the reasons for cardiac surgery cancelation (94). 
Szekely et al (32) showed an association between the amount of blood product 
transfusions and risk of death, dialysis, low output syndrome, pulmonary failure and 
infection. An increase in morbidity results in prolonged hospital stay, increasing the 
cost of patient management (32). 
1.11 A review on blood utilisation practices in paediatric cardiac 
surgery 
Jobes et al (57) conducted a 15 year retrospective cohort study on children less than 
two years of age which showed a decrease in transfusion requirements if fresh whole 
blood was given. Information about issued blood product units by blood bank was 
analysed, and the blood product units were considered transfused if they were not 
returned back to blood bank within a certain period. This study reported the following 
means (SD) for transfused blood product units: whole blood 1.5 (0.6); RPC 1.3 (1.3); 
FFP 0.1 (0.4); platelets 0.3 (0.6); and cryoprecipitate 0.2 (0.6). 
Keung et al (95), in a retrospective audit of hospital transfusion of RPC units showed 
that 41,4% of units where transfused in the perioperative period, and of these 49,2% 
were given intraoperatively. They found that in cardiac surgery, 1663 units of blood 
were transfused and most transfusions in CPB cases were intraoperatively (74,3%) 
and in off CPB cases, preoperatively and postoperatively. 
A cohort study conducted by Whitney et al (96), in 2013, showed a decrease in 
transfusion of RPC and cryoprecipitate post CPB following implementation of an 
algorithm in children less than six months old. Iyengar et al (46) used mainly RPC 
and FFP intraoperatively and a few patients received platelet and cryoprecipitate. 
In Germany, cardiac surgery was found to be second to the Haematology/Oncology 
department in increased blood utilisation, and this led to the implementation of a 
blood management program to monitor blood usage in cardiac surgery throughout 
the patients stay in hospital. The program was aimed to check if blood products are 
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transfused appropriately by following guidelines at the institution in order to decrease 
cost and morbidities related to transfusion. (97) 
In an audit by Keung et al (95) in patients at the Royal Children’s Hospital in 
Melbourne, an increased perioperative RPC (2359 units) (41%) usage in cardiac 
surgery, particularly intraoperatively on CPB, was shown. Though the audit by Wade 
et al (98), in paediatric patients, was not on cardiac patients, it showed that by having 
set transfusion protocols it is possible to assess if blood products were given 
appropriately.     
1.12 Conclusion   
There are multiple factors that increase the risk of blood product transfusion during 
paediatric cardiac surgery on CPB. It is essential to understand and optimise the 
physiological status of the patient prior to surgery, and to comprehend the effects that 
CPB has on blood product transfusion. Proper blood product transfusion planning in 
conjunction with point of care coagulation testing is necessary for the reduction of 
blood product transfusion.  
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SECTION 2 
Journal guidelines to authors 
 
The formatting complies with the formatting of Health Science style guide for Thesis, 
dissertations, and Research Report. Please note that the formatting of the draft 
article may differ from the research report in order to comply with the authors’ 
instructions. 
Journal: Cardiovascular Journal of Africa 
Information for authors  
The Cardiovascular Journal of Africa is pleased to consider original articles, reviews, 
discussions on topical issues, case studies, meeting reports and other contributions 
relevant to the understanding, treatment and care of vascular disease. 
Original articles and reviews are sent for independent peer-review. Material is 
accepted for publication on the understanding that it has not been published 
elsewhere. Authors will be asked to confirm this in writing and transfer copyright to 
the Journal. 
Authors submitting papers to CVJA should also register as a reviewer as a quid pro 
quo for authors for reviewers reviewing your submission. If authors do not register as 
reviewers it may be taken in consideration when deciding on acceptance and 
rejection, and the time of publication. We do try not to call on a reviewer more than 
once a year but in rare circumstances it may be twice.  
Manuscript processing fee (effective 1 January 2016)  
It has become necessary for the Cardiovascular Journal of Africa to charge a modest 
manuscripts processing fees for all articles submitted for publication. 
• South African and African Authors: ZAR 1000 
• International Authors: ZAR 2000 
This is normal for most, if not all, journals. We so far have been able to survive 
without charging authors for submissions but can no longer do so. We regret that we 
have to implement this as from the 1st of January 2016. Payment will need to be 
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made online and once payment has been received, the manuscript will be further 
processed for possible publication.  
This payment is a processing fee and does not guarantee publication of the article. 
The processing fee is not refundable in the event of rejection as processing cost will 
have been incurred. (Payment can be made online with a valid credit card) 
Guidelines for authors and readers of the CVJA 
The Cardiovascular Journal of Africa (CVJA), which incorporates the Cardiovascular 
Journal of South Africa, is particularly concerned with publication of scientific articles 
related to Cardiac and Vascular conditions and situations, concerning adults and 
children, in Sub Saharan Africa. But will accept articles from all parts of the world.  
Basic Science publications related to clinical aspects either for elucidation, in-depth 
understanding or therapeutic approaches are accommodated. The Journal functions 
as official medium for other related societies which do not as yet have own Journals 
such as, Hypertension, Stroke, Nuclear Medicine and Magnetic Resonance in 
Cardiology, Paediatrics, Molecular and Cellular Cardiology, and Vascular disease in 
Diabetes and Obesity. 
Index Medicus / PubMed Central / Medline and Sabinet lists the Journal for indexing 
and electronic citation. A printed version and an electronic version for citation and 
publication of abstracts are produced. The abstracts of articles published appear on 
PubMed with a link out to Sabinet to give access to full text retrieval of published 
material. In order to improve visibility for our authors, the CVJ Africa is now also able 
to index articles for PubMed Central. 
Article submissions 
All categories of manuscripts for the Cardiovascular Journal of Africa must be 
submitted on-line to Editorial Manager. You will be assigned your own password and 
user name. This will allow complete interaction between the editor and authors. 
Internally, reviewers will be approached to review material in their field of expertise 
and assigned with similar interaction. All information will be entirely protected and 
confidential.  
All submissions should be written in a clear and succinct manner, following the style 
of the Journal. Title page should include a descriptive title; authors’ surname and 
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forename, address of each author and full address, telephone, fax and e-mail 
contacts for the corresponding author. In text: tables and figures are either inserted 
as part of sentence, for example Table 1, or in parentheses, for example (Fig. 1). 
Each table should carry a descriptive heading.  
Editorial Manager will clearly indicate which aspects of the submission must be 
supplied off-line (download off-line document). This must be provided to the Journal 
by fax or mail (fax number +27 21 976 8129 or PO Box 1013, Durbanville, 7551) or e-
mail to info@clinicscardive.com 
All images MUST be at or above intended display size, with the following image 
resolutions: Line Art 800 dpi, Combination (Line Art + Halftone) 600 dpi, Halftone 300 
dpi Image files also must be cropped as close to the actual image as possible. 
Preferred Image Format Alternative Image Format 
Image Format .tif .jpg 
Image Width Greater than or equal to  
intended display size 
Greater than or equal to  
intended display size 
Colorspace RGB RGB 
DPI 500+ 500+ 
Alpha Channels None  
Layers Flattened  
Compression quality  Maximum 
 
References numbered in the order of appearance in the text, according to Vancouver 
style. For articles: Author AB, Author C, Author M. The title of the article. Abbreviated 
journal title 1999; 14: 172–183. For book chapters: Author AB, Author CD. The title of 
the chapter. In: Editor A, Editor BC, ed. Title of the book, 2nd edn. Location: 
Publisher, 1999: 133 –139. DOI Numbers / PMID (Pubmed ID / PMC ID) must be 
added to all references to facilitate tagging for PubMed Central. 
Original articles: Title page as above. Abstract (150 words) a short inclusive 
statement suitable for direct electronic abstracting, identifying the purpose of the 
study, key methods, the main results and the main conclusion. Keywords: maximum 
of six keywords for indexing. Introduction: concise description of background, 
sufficient for the non-specialist to appreciate the context of the work. Clear statement 
30 
 
of the purpose of the study. Methods: a brief description of study design, procedures, 
analytical techniques and statistical evaluation. Results: a clear account of the study 
findings using quantitative language where possible and cross-referenced to tables 
and figures.  Discussion: an interpretation of the study placed within the context of 
current knowledge, leading to specific conclusions where possible. 
Acknowledgements. References, figures and tables as above. 
Reviews 
Title page as above. Abstract (150 words) setting out the scope, key messages and 
conclusions of the review. Body of text liberally partitioned with headings and 
subheadings leading to a synopsis with conclusions at the end. Key messages in a 
separate box itemising two to five short principal statements. Acknowledgements, 
references, tables and figures as above. 
Other articles should adopt a concise style consistent with similar articles previously 
published in the journal. Manuscripts should include a title page, and appropriate 
subheadings for text. Style of tables, figures and references as above. 
Figures be sent to us in a high resolution JPEG format, but they MUST be sent 
separately from the Word document. If not in high resolution JPEG, then PowerPoint 
will do. Editorial Manager will clearly indicate which aspects of the submission must 
be supplied off-line (download off-line document). This must be provided to the 
Journal by fax or mail (fax number 0866 644 202 or PO Box 1013, Durbanville, South 
Africa, 7551) or e-mail to info@clinicscardive.com. 
The status of progression of the peer-review system will be directly accessible by 
authors. The Editorial Manager system is particularly useful to authors and reviewers 
as there is a direct link to PubMed for viewing all related articles on the subject 
matter. 
Submitted manuscripts must be supplied with a covering letter with any additional 
information that may be helpful to the editor, such as the type or format of article that 
the manuscript represents. If the manuscript has been submitted previously to 
another journal, it is helpful to include the previous editor's and reviewers' comments 
with the submitted manuscript, along with the authors' responses to those comments. 
Copies of any permission to reproduce published material, to use illustrations or 
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report information about identifiable people, or to name people for their contributions 
must accompany the manuscript. 
Editorial Policy 
Statements and opinions expressed in articles and communications in CVJA are 
those of the authors and not those of the Editor or publisher. The Editor and 
publisher disclaims any responsibility or liability for such views. Neither the Editor nor 
the publisher guarantees, warrants or endorses any product or service advertised in 
this publication; neither do they guarantee any claim made by the manufactures of 
such product or service. 
Material submitted for publication in the Cardiovascular Journal of Africa is accepted 
on condition that it has not been published elsewhere. The management reserves the 
copyright of the articles published. Aspects of cardiovascular medicine related to 
Sub-Saharan Africa will be encouraged.  
Authors submitting papers to CVJA should also register as a reviewer as a quid pro 
quo for authors for reviewers reviewing your submission. If authors do not register as 
reviewers it may be taken in consideration when deciding on acceptance and 
rejection, and the time of publication. We do try not to call on a reviewer more that 
once a year but in rare circumstances it may be twice. 
Online first: advanced online publication ahead of print 
The Cardiovascular Journal of Africa is launching an online First Advance Online 
Publication (ePublication ahead of print) with full text availability via Pubmed and this 
website which is accessible via Google and other search engines. 
This facility is also known internationally as E-publication, ahead of print and offers 
authors the opportunity to publish their research articles sooner for an international 
audience. 
Articles published online with CVJA will be published with unique DOI numbers, 
which ensures that the article can be cited using the date of the manuscript’s first 
online posting and its DOI number. DOI’s provide a persistent, permanent way to 
identify manuscripts in an electronic environment and are generated via our Editorial 
Management system and in accordance with the policy of the DOI foundation. 
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An example, of how articles are cited first online and then in print version is provided 
below: 
Webster I et al. AMP Kinase activation and glut4 translocation in isolated 
cardiomyocytes. Cardiovasc J Afr. Prepublished month, day, year. DOI: 
10.5830/CVJA-2011-042 
The initial Pubmed citation will be updated after the print version appears. 
Cost of First Advance Online Publication (Payment can be made online with a 
valid credit card) 
ZAR 4000 for Authors outside of Africa 
ZAR 1500 for African Authors (including South Africa) 
Please note that the Online First option is only available once your article has been 
accepted for publication. Also note there will be no refunds, any payment made 
before an article is accepted / rejected will be forfeited. 
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Abstract 
Background 
Cardiac surgery is associated with perioperative bleeding which may result in the 
need for blood transfusion, particularly in paediatric congenital cardiac surgery on 
cardiopulmonary bypass (CPB). There is a need for regular auditing in order to 
improve practices.  
Methods  
Retrospective, contextual, descriptive data of 105 patients were collected for the 
period January to December 2014.  
Results  
The median age of patients was 4 (1–6) years, weight 13 (8.4–20) kg, with mean 
lowest CPB haemoglobin of 8.3 (1.5) g/dL. There was a statistically significant 
difference in median red packed cells (RPC), platelets and cryoprecipitate units per 
patient transfused across four Risk Adjusted classification for Congenital Heart 
Surgery categories (p=0.03, p=0.0013, p=0.0001 respectively). There was 
statistically significant correlation between transfused fresh frozen plasma units with 
CPB time (r=0.2634, p=0.0199) and RPC units (r=-0.4654, p<0.001).  
Conclusion 
Although no standardised transfusion guidelines were available, overall blood 
product transfusion was comparable to reported practices. 
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Introduction 
Blood products are a scarce commodity in South Africa, as reported by the South 
African National Blood Service. (1) Cancellation of surgical cases has been reported 
due to depletion of blood products from the blood blank. (2) Blood products are 
transfused commonly in paediatric cardiac surgery on cardiopulmonary bypass 
(CPB). (3) Blood product transfusion is intended to treat anaemia, improve oxygen-
carrying capacity and oxygen delivery to tissues, and to maintain haemostasis. (4)  
Transfusion of blood products is not without complications, and can result in 
haemolytic and non-haemolytic adverse reactions. (5) In paediatric cardiac surgery on 
CPB, blood product transfusion has been associated with cardiovascular instability, 
acute kidney injury, (6) delayed extubation time,(7) prolonged mechanical ventilation, 
infection, (6, 8, 9) and increased risk of postoperative bleeding. (10) 
The World Health Organisation (WHO) recommends the provision of disease-free 
blood products, and the promotion of appropriate usage of blood products by health 
care providers. (11) The implementation of blood conservation strategies to reduce 
blood product transfusion in paediatric cardiac surgery is recognised by the WHO. (12) 
These strategies have made it possible to perform bloodless paediatric cardiac 
surgery on CPB, (13) and have also been used successfully in Jehovah’s Witness 
patients. (14, 15) 
Blood transfusion guidelines are available for adult cardiac surgery patients, (16) but 
could not be found for paediatric patients. The lack of standardised guidelines in 
paediatrics cardiac surgery could be because of multiple factors that influence blood 
product transfusion in this patient population. (6) There are still controversies 
regarding the safest haemoglobin on CPB in paediatric cardiac surgery. (13, 17-19) A 
randomised controlled trial, from the Boston Children’s Hospital, revealed a poor 
psychomotor developmental index after a year in young patients with a range of 
congenital cardiac conditions with haematocrits below 21.5% on CPB. (17) In contrast, 
no neurodevelopment impairment was observed in older patients (13) and infants (18) 
with a haematocrit below 20% presenting for low risk cardiac conditions. There were 
no outcome differences reported between the liberal (9.5 g/dL) and restrictive (7 
g/dL) haemoglobin strategies during the postoperative period in paediatric patients 
post acyanotic cardiac surgery in one study. (19)  
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The WHO requires appropriate blood product use by health care providers, which 
can be assessed by regular audits. Although the appropriateness of blood product 
transfusion during cardiac surgery is undefined, it is essential to audit institutional 
practices. Audits are intended to evaluate practices and identify the need to change 
or modify these practices to improve blood product utilisation. This study aimed at 
evaluating transfusion practices in paediatric patients at a tertiary hospital as our 
practice had not been audited previously. The objectives of the study were to 
primarily describe the demographic and clinical characteristics of the study 
participants, and secondarily to assess the differences in the transfused blood 
product units between RACHS categories and patients’ weight categories. 
Methods 
A retrospective, contextual, descriptive study was conducted at Charlotte Maxeke 
Johannesburg Academic Hospital. Approval to conduct the study was obtained from 
the Human Research Ethics Committee (Medical) and other relevant authorities. 
Informed consent was not required as this was a retrospective study. Data were 
collected by one author (CTB). Patient confidentiality was maintained by assigning 
numbers to patient data, and raw data was accessed by the author and supervisor. 
Data were collected for patients younger than 18 years of age who underwent 
cardiac surgery on CPB for congenital heart disease during the period between 1 
January and 31 December 2014. The charts of the anaesthetists, perfusionists, and 
the ICU were reviewed for relevant data. Data collected included patient 
demographics, cardiac lesion and operation, preoperative platelet count, 
perioperative anticoagulation therapy, perioperative haemoglobin, CPB time, aortic 
cross-clamp (AOX) time and intraoperative blood products used. Blood products 
transfused were represented as units of products transfused to the patients as the 
practice in the department is not that of documenting products by millilitres. The 
practice also involves transfusion over a period of time of products commenced 
intraoperatively, into the postoperative period (no longer than four hours for RBCs 
and 30 minutes after thawing for fresh frozen plasma (FFP)). A unit of RPC has a 
volume of approximately 300 mls, FFP approximately 225 mls, platelets 
approximately 160 mls, and cryoprecipitate approximately 15 mls. Patients who were 
Jehovah’s Witness, and patients with missing or illegible data were excluded. 
Data collection, management and processing was performed using Microsoft® Excel 
for Windows, and the analysis was conducted using Stata ®14 (StataCorp.2015, 
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Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). 
Descriptive analysis were done using tables of frequencies and percentages, mean 
(SD) and median (IQR) where appropriate, and were presented according to Risk 
Adjusted classification for Congenital Heart Surgery (RACHS) categories as this 
denotes the complexity of the cardiac surgery. (20) The Kruskal-Wallis and One-way 
Anova analysis of variance were conducted to determine the median or mean 
differences of clinical variables across RACHS and weight categories. The Dunn’s 
comparison with Holm-Sidak stepwise adjustment was performed as a post-hoc test 
to the Kruskal-Wallis to find where the statistical significant difference was between 
the groups with statistical significant differences. A pairwise correlation test was 
performed to assess the linear relationship between RPC, FFP, and CPB time. A p-
value less than 0.05 was considered statistically significant.  
Results 
A total number of 121 patients were eligible to be included in the study. Of these, 16 
patients were excluded due to missing data pertaining to preoperative results (4), 
anaesthetic charts (2), perfusionist charts (5), and intensive care unit charts (5). 
There were 6 (5.7%) redo surgery patients who were included in the study as their 
primary surgery had been undertaken outside of the study period. No patients were 
included in the study more than once. 
The patient demographics are presented in Table 1.1 according to patients’ 
respective RACHS categories. There were no patients in RACHS category 5; 
therefore, the category is excluded from the tables. 
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Table 1. 1 Demographics according to RACHS category 
Parameter RACHS 1 RACHS 2 RACHS 3 RACHS 4 
Demographics 
Patient n (%) 13 (12.4) 62 (59)  27 (25.7) 3 (2.9) 
Male n (%) 5 (9.4) 34 (64.2) 12 (22.6) 2 (3.8)  
Female n (%) 8 (15.4) 28 (53.8) 15 (28.8) 1 (1.9) 
Age (yr) Median(IQR) 5.5 (3.5 - 6.25) 4 (1 - 6) 4 (1 - 7) 0.08 (0.08 -1.04) 
Wt (kg) Median (IQR) 18 (13 - 20) 12 (9 - 19) 13 (8 - 22) 3.4 (3.3 - 3.45) 
Congenital heart lesions n (%) 
ECD 11 (25.6) 21 (48.8) 11 (25.6) 0 (0) 
GVA 2 (28.6) 0 (0) 2 (28.6) 3 (42.9) 
TOF 0 (0) 28 (100) 0 (0) 0 (0) 
Valve abnormal 0 (0) 13 (56.5) 10 (43.5)  0 (0) 
CC abnormal 0 (0) 0 (0) 4 (100) 0 (0) 
*Wt-weight; ECD-endocardial cushion defects; GVA-great vessel anomalies; TOF-Tetralogy of Fallot; CC-cardiac chamber; 
RACHS-Risk Adjusted classification for Congenital Heart Surgery 
The preoperative haemoglobin and platelet count are presented in Table 1.2. There 
was no significant difference in preoperative platelet count, and preoperative 
haemoglobin across RACHS categories. 
Table 1. 2 Preoperative platelet count and haemoglobin 
Parameters 
Mean (SD) 
RACHS 1 
 
RACHS 2 
 
RACHS 3 
 
RACHS 4 
 
p value 
Platelets (109/L) 317.3 (89.8) 294.8 (128.7) 327 (144.6) 277.7 (96.4) 0.855 
Hb (g/dL) 12.7 (1.3) 14.7 (3.7) 14.3 (3.6) 11.1 (2.6) 0.16 
*RACHS-Risk Adjusted classification for Congenital Heart Surgery, Hb-haemoglobin 
Records showed that aspirin was administered preoperatively in only 3 (2.9%) 
patients with no doses documented, and these patients where from RACHS category 
2. A bolus dose of 300 to 500 IU/kg heparin was given by anaesthetists before 
initiation of CPB. The perfusionists administered additional heparin during CPB with a 
mean (SD) dose of 1.8 (1.4) mg/kg. 
The type of CPB clear fluid prime for the 105 patients was not clearly stated on the 
charts. Ten out of 105 (9.5%) patients did not receive clear prime fluid on CPB. The 
median (IQR) fluid volume used was 800 (500–1000). Albumin was added to the 
CPB in 32 (30.5%) patients at a mean (SD) dose of 9.7 (4.1) ml/kg. 
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The median values for AOX and CPB time in minutes between the RACHS 
categories are shown in Table 1.3.  AOX and CPB times were statistically 
significantly different between RACHS scores. There was a statistically significant 
relationship between FFP units transfused with CPB time (r=0.2634, p=0.0199), and 
RPC units (r=-0.4654, p<0.001) transfused. 
Table 1. 3 CPB and AOX time in minutes according to RACHS category 
Parameter  
Median (IQR) 
RACHS 1 RACHS 2 RACHS 3 RACHS 4 p value 
AOX time (min) 18.5 (11- 40.5) 76 (50- 123.5) 89 (57- 120) 157 (112- 193) 0.0002* 
CPB time (min)  55 (50- 97.5) 123 (94.5- 89.5) 143 (100- 198) 294 (257- 447) 0.0001* 
* p < 0.05; AOX-aortic cross clamp; CPB-cardiopulmonary bypass; RACHS-Risk Adjusted classification for Congenital Heart 
Surgery 
Table 1.4 shows units of blood product transfused according to RACHS categories. 
Platelets and cryoprecipitate were given solely by anaesthetists. Only 2 (1.9%) 
patients had a transfusion-free operation and they were from the RACHS category 1. 
Table 1. 4 Blood product units transfused according to RACHS category 
Products n (%) RACHS 1 RACHS 2 RACHS 3 RACHS 4 Total 
RPC 
Total  11 (9.9) 66 (59.5)  28 (25.2)  6 (5.4) 111 (100) 
Anaesthetists 0 (0) 8 (7.2) 2 (1.8) 1 (0.9) 11 (9.9) 
Perfusionists 11 (9.9) 58 (52.3) 26 (23.4) 5 (4.5) 100 (90.1) 
FFP 
Total  2 (3.4) 41 (70.7)  15 (25.7) 0 (0) 58 (100) 
Anaesthetists 2 (3.4) 21 (36.2) 12 (20.7) 0 (0) 35 (60.3) 
Perfusionists 0 (0) 20 (34.5) 3 (5.2) 0 (0) 23 (39.7) 
Platelets (Anaesthetists) 0 (0) 16 (51.6) 11 (35.5) 4 12.9) 31(100) 
Cryoprecipitate (Anaesthetists)  0 (0) 17 (60.7) 6 (21.4) 5 (17.9) 28 (100) 
*RPC-red packed cells; FFP-fresh frozen plasma; RACHS-Risk Adjusted classification for Congenital Heart Surgery 
A Kruskal Wallis test showed a statistically significant difference between median 
RPC, cryoprecipitate, and platelet units transfused between RACHS categories 
(Table 1.5). A post-hoc Dunn’s test for the median RPC, cryoprecipitate, and platelet 
units transfused showed the statistically significant difference to be between RACHS 
4 and the other three RACHS categories (1, 2 and 3) (Table 1.6). Additionally, a 
statistically significant difference was found between RACHS category 3 and 1 for 
platelet unit transfusion (Table 1.6).  
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Table 1. 5 Median blood product units per patient transfused by RACHS 
category 
Products  
RACHS 1 RACHS 2 RACHS 3 RACHS 4 Total  p value 
Median (IQR) 
RPC 1 (1-1) 1 (1-2) 1 (1-1) 2 (2-2) 1 (1-1) 0.03* 
FFP 0 (0-0) 0.5 (0-1) 0 (0-1) 0 (0-0) 0 (0-1) 0.053 
Platelets 0 (0-0) 0 (0-1) 0 (0-1) 1 (1-2) 0 (0-1) 0.0013* 
Cryoprecipitate 0 (0-0) 0 (0-0) 0 (0-0) 1 (1-3) 0 (0-0) 0.0001* 
* p < 0.05; RPC-red packed cells; FFP-fresh frozen plasma; RACHS-Risk Adjusted classification for Congenital Heart Surgery 
Table 1. 6 Post-hoc Dunn test of blood product use between RACHS categories 
Product Categories RACHS 4 RACHS 3 RACHS 2 
RPC  
K Wallis  
p value = 0.030* 
RACHS 1 0.009* 0.321 0.302 
RACHS 2 0.018* 0.405  
RACHS 3 0.022*   
Platelets 
K Wallis  
p value = 0.001* 
RACHS 1 0.001* 0.021* 0.065 
RACHS 2 0.005* 0.123  
RACHS 3 0.021*   
Cryoprecipitate 
K Wallis  
p value = 0.0001* 
RACHS 1 <0.001* 0.256 0.349 
RACHS 2 <0.001* 0.217  
RACHS 3 <0.001*   
* p < 0.05; RPC-red packed cells; RACHS-Risk Adjusted classification for Congenital Heart Surgery 
Taking into consideration the small sample size in RACHS 4, a further analysis of the 
RACHS categories into two groups consisting of RACHS 1 and 2, and RACHS 3 and 
4, was undertaken and found similar results for platelets and cryoprecipitate (Table 
1.7). The significant difference was lost for RPCs. 
Table 1. 7 Median blood product units per patient transfused between two 
RACHS category 
Products RACHS 1+2 RACHS 3+4 Total  p value 
RPC 1 (1- 1) 1 (1-1) 1 (1-1) 0.4359 
FFP 0 (0-1) 0 (0- 1) 0 (0-1) 0.5218 
Platelets 0 (0- 0) 0 (0- 1) 0 (0-1) 0.0162* 
Cryoprecipitate  0 (0- 0) 0 (0- 0) 0 (0-0) 0.0254* 
* p < 0.05; RPC-red packed cells; FFP-fresh frozen plasma; RACHS-Risk Adjusted classification for Congenital Heart Surgery 
The mean perioperative haemoglobin levels according to RACHS categories are 
shown in Figure 1 and Table 1.8. There was no significant difference in mean 
perioperative haemoglobin levels across the RACHS categories. 
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Figure 1: Perioperative haemoglobins categorised by RACHS categories 
 
*CPB-cardiopulmonary bypass; ICU-intensive care unit; RACHS-Risk Adjusted classification for Congenital Heart Surgery; 
preop-preoperative 
Table 1. 8 Perioperative haemoglobins across the RACHS categories 
Haemoglobin (g/dL)  RACHS 1 RACHS 2 RACHS 3 RACHS 4 p value 
Preoperative 12.6 (1.3) 14.7 (3.6) 14.3 (3.6) 11.1 (2.6) 0.16 
Initial CPB 8.5 (1.4) 9.1 (1.8) 9.3 (1.5) 8.9 (2.6) 0.61 
Lowest CPB 8.3 (1.4) 8.3 (1.6) 8.5 (1.2) 7.2 (1.2) 0.42 
Last CPB 8.9 (1.3) 9.4 (1.3) 9.7 (1.2) 10.3 (1.4) 0.33 
Initial ICU 12.5 (1.3) 12.1 (2.1) 11.8 (1.9) 11.2 (1.8) 0.72 
*CPB-cardiopulmonary bypass; ICU-intensive care unit; RACHS-Risk Adjusted classification for Congenital Heart Surgery 
The median blood product units by weight categories are presented in Table 1.9. The 
RPC, platelets, and cryoprecipitate units transfused were statistically significant 
across the weight categories. A post-hoc Dunn’s test showing where the difference 
lies between weight categories with regards to cryoprecipitate and RPC unit 
transfusion shows differences predominantly between weight category >15 kg and 
other categories, whilst platelet unit transfusion differences were between weight 
categories < 6 kg and 6 to 15 kg (Table 1.10).  
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Table 1. 9 Median blood product unit transfusion by weight 
Categories  
Products  
Weight <6 kg 
(n=11) 
Weight 6- 15 kg 
(n=52) 
Weight > 15 kg 
(n=42) 
K Wallis  
p value 
RPC 1 (1-2) 1 (1-1) 1 (0-1) 0.001* 
FFP  0 (0-0) 0 (0-1) 1 (0-1) 0.087 
Platelets  1 (0-1) 0 (0-0) 0 (0-1) 0.038* 
Cryoprecipitate 0 (0-1) 0 (0-0) 0 (0-0) 0.009* 
* p < 0.05; RPC-red packed cells; FFP-fresh frozen plasma 
Table 1. 10 Post-hoc Dunn test of blood product use between weight categories 
Products RPC Cryoprecipitate Platelets 
Categories <6 kg 6-15 kg <6 kg 6-15 kg <6 kg 6-15 kg 
6-15 kg 0.096   0.049*   0.019*   
>15 kg 0.002* 0.002* 0.004* 0.043* 0.099 0.097 
* p < 0.05; RPC-red packed cells 
The blood conservation strategies employed were the use of tranexamic acid, cell 
salvage, and ultrafiltration. A single-blood conservation strategy was used in 36 
(34.3%) patients, and two strategies in 45 (42.9%) patients. All three strategies were 
used in 16 (15.2%) patients, whilst 8 (7.6%) patients had no blood conservation 
strategy used. 
Discussion 
The current study was very difficult to analyse because of multiple variables which 
influence perioperative blood product usage, of which some were not assessed. 
Guidelines to audit whether blood products were appropriately transfused in 
paediatric cardiac surgery were not identified. It was also difficult to compare results 
with literature because of the vast variety within the patient population. 
Documentation of blood product amounts transfused by both the anaesthetists and 
perfusionists were in units and not in millilitres similar to data in a study by Jobes et 
al. (21) 
In the current study, patients were categorised according to the RACHS category as 
it signifies the complexity of the congenital cardiac lesion and surgery. (20) There was 
an increase in the progression of blood product transfusion across the RACHS 
categories. Patients in RACHS category 4 had a higher transfusion rate for RPC, 
platelets, and cryoprecipitate than other groups. These patients were younger and 
had prolonged CPB and AOX time.  
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Studies by Kipps et al. (9) and Szekely et al. (6) also demonstrated that the above 
factors are associated with increased transfusion of blood products. No FFP was 
transfused in the RACH category 4 patients with preference shown for 
cryoprecipitate, which contains concentrated clotting factors in a small volume. (5) 
This allowed for haemostasis to be achieved without the complication of fluid 
overload in the patients. 
Bloodless paediatric cardiac surgery has been performed successfully with the use of 
miniature circuits. (13, 14, 18, 22) At our institution, miniature CPB circuits were not 
utilised at the time of the audit. Perhaps this was the reason for only 1.9% of cardiac 
surgical cases having bloodless surgery in the current study. Miniature circuits have 
also resulted in a decrease in the volume of RPC transfusion without an increase in 
morbidity or mortality. (23) Studies by Redlin et al. (24) and Miyaji et al. (18) showed 
higher rates of bloodless cardiac surgery (48%) on patients below 16 kg of weight, 
and 64% on patients less than 7 kg of weight. A one-year retrospective study by 
Durandy et al. (25) reported 61% of patients between 6 to 15 kg having undergone 
bloodless cardiac surgery.  
The blood products mostly transfused were RPC and FFP, with perfusionists mainly 
transfusing RPC and anaesthetists transfusing RPC, FFP, cryoprecipitate and 
platelets. The reason for this might be that the perfusionists primed the CPB circuit 
with RPC to prevent haemodilution associated with large-volume CPB circuits. (22) As 
a result, the haemoglobin levels were not significantly different across the RACHS 
categories throughout the perioperative period. There was an overall decrease in 
haemoglobin from preoperative levels on initiation of CPB, and an increase to 
haemoglobin > 10 g/dL on arrival in ICU. A similar perioperative haemoglobin pattern 
was seen in the cohort study by Redlin et al. (24) in their blood transfusion group. This 
demonstrates the appropriate use of RPC in maintenance of haemoglobin levels. 
The anaesthetists transfused FFP, cryoprecipitate, and platelets at the end of CPB 
empirically to manage bleeding. Only activated clotting time was used as a point of 
care test, which did not give information about the state of other coagulation system 
components. A recent cohort by Machovec et al. (26) in infant cardiac surgery showed 
a decreased transfusion exposure with the use of a haemostasis management 
system compared to activated clotting time. It has become common practice to use 
intraoperative point of care tests to assess the coagulation status of patients before 
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transfusion of blood products, as well as blood management programmes in 
paediatric cardiac surgery. (23, 27) This practice has resulted in decreased blood 
product transfusions when used in conjunction with algorithms. (26-29) Testing of 
fibrinogen and platelet function during rewarming has resulted in decreased 
cryoprecipitate transfusion post CPB in a cohort by Machovec et al. (29)  
Although there were no blood usage protocols at our institution, the mean 
haemoglobin on CPB of 8.3 (1.5) g/dL was attained, which is comparable with 
haemoglobin trigger levels of 7- 8 g/dL observed in other studies. (24, 25) Even though 
transfusion triggers are set, transfusion of blood products should be individualised to 
the clinical condition of the patient. (4, 30)  
In this study, an expected statistically significant difference was shown in CPB and 
AOX time across RACHS categories. There was a statistically significant correlation 
between FFP units transfused with CPB time, and RPC units transfused. Jenkins et 
al. (20) had concluded that a high RACHS category signifying the complexity of the 
surgery was associated with long CPB time, which increased the risk of blood 
product transfusion. A study by Redlin et al. (24) revealed a significant association 
between transfusion and CPB time (OR=1.02 CI=1.01-1.03, p=< 0.0001). Another 
study by Salvin et al. (31) showed that patients with an increased CPB and AOX time 
were transfused more blood products postoperatively.  
In the current study, when secondary analysis was conducted by categorising data 
according to weight, there was no significant difference with median FFP transfusion 
between the weight categories. There was a statistically significant difference in 
RPC, cryoprecipitate and platelets transfusion between the weight groups. Studies 
have shown that low weight is associated with an increase in blood product 
transfusion. (9, 32) 
There are no protocols on the administration of conservation strategies at our 
institution, but the majority of patients utilised some form of blood conservation 
strategy, singly or in combination. The impact of the different strategies on blood 
product use was not assessed as it was beyond the scope of this study.  
Only 2.9% of patients received aspirin in the current study, and the bleeding risk was 
not assessed because there was no point of care testing. Aspirin has been 
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associated with increased RPC transfusion in adult cardiac surgery, (30) but had no 
effect on bleeding and transfusion in paediatric cardiac surgery. (31)  
The current study was retrospective, and depended on the availability of records and 
record-keeping by colleagues. The study did not look at temperature, metabolic state 
of the patient, or intraoperative bleeding which may have contributed to transfusion. 
The study also did not differentiate between cyanotic and acyanotic cardiac lesions 
as data were not clear on this. Further studies should be conducted to demonstrate if 
there is a relationship between our practice and morbidity and mortality. Transfusion 
protocols together with the utilisation of point of care test should be considered. 
Conclusion 
The use of RPC was different between RACHS categories whilst maintaining similar 
haemoglobin levels despite the absence of set transfusion triggers and miniature 
circuits. The pattern of haemoglobin maintenance was similar to one study. The 
transfusion of other blood products was empirical as no point of care tests were 
utilised. The use of triggers, algorithms, and point of care testing in paediatric cardiac 
patients may result in a decreased level of blood product transfusion. 
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SECTION 4 
Appendices 
Appendix 1: Human Research Ethics Committee (Medical) approval  
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Appendix 2: Postgraduate approval 
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Appendix 3: Data collection spreadsheet 
Participant number 1 2 3 4 5 6 
Demographics        
• Age       
• Gender       
• Weight       
• Cardiac lesion       
• Aortic cross clamp time       
• CBP time       
• Resternotomy operations       
Preoperative anticoagulant       
Platelets preoperative       
CPB prime       
• Fluid type       
• Volume (ml)       
• Anticoagulant        
HB       
• Before CPB       
• During CPB       
• After CPB       
Anaesthetist blood product 
volume (ml) 
      
• RBC       
• FFP       
• Platelet       
• Cryoprecipitate       
Perfusionist blood product 
volume (ml) 
      
• RPC       
• FFP       
• Platelet       
• Cryoprecipitate       
Blood conservation strategies       
• Cell saver       
• Autologous transfusion       
• Miniature CPB       
• Antifibrinolytic agent       
• Ultrafiltration       
• Other        
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Introduction 
The use of blood products has evolved from transfusion of animal blood to humans 
and then human blood to humans (1). Blood product transfusion has become a 
common practice in paediatric cardiac surgery on cardiopulmonary bypass (CPB) (2). 
This is because of these patients’ small body size and blood volume relative to the 
CPB circuit size (2-7).  
Blood products are transfused to treat anaemia, improve oxygen carrying capacity, 
improve oxygen delivery to tissues, and to maintain haemostasis (8). The most 
commonly used blood products in cardiac surgery are red packed cells, fresh frozen 
plasma, platelet, and cryoprecipitate. Although benefits to transfusing blood products 
exist, this practice is costly and hence the need for blood products to be infused only 
when there are valid indications. Adverse reactions due to blood product transfusion 
are a concern as are transfusion transmitted infections although they do not occur 
commonly (9-11).  
The transfusion of blood products in paediatric cardiac surgery on CPB is associated 
with prolonged mechanical ventilation, infection, (4, 12, 13), cardiovascular instability 
(4), and acute kidney injury (4, 14). These morbidities may result in the patient 
staying in the intensive care unit or hospital for prolonged periods thereby increasing 
the cost of managing a single patient.  
There are blood conservation strategies that have been implemented to reduce blood 
product transfusion during paediatric cardiac surgery. These includes the use of 
miniature CPB circuits (15, 16) and ultrafiltration (17, 18), which also decreases the 
inflammatory response associated with CPB (5, 19-21), cell salvaging (17, 22) and 
preoperative autologous donation (23, 24). The use of antifibrinolytic agents has also 
shown a decrease in postoperative blood loss (25-27). 
One of the objectives of the World Health Organisation is to promote the appropriate 
use of blood products (28).The Society of Thoracic Surgeons and the Society of 
Cardiovascular Anaesthesiologists Blood Conservation Clinical Practice Guidelines 
are guidelines established from adult cardiac patients, and are not clear on the use in 
the paediatric patient specifically (7). However, there are several studies done in 
paediatric patients with trigger haemoglobin levels on CPB of 7-8 g/dL for the patient 
coming for cardiac surgery (5, 6, 20, 29). Though triggers have been set, the general 
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condition of the patient should also be monitored to guide on the need for transfusing 
(8, 30, 31) in order to avoid complications due to a low haemoglobin (29).  
Wypij et al (29) conducted a randomised control trial of haematrocit strategies during 
infant cardiac surgery using hypothermic CPB. The group with a mean haematocrit of 
around 20% had a high fluid balance, high lactate an hour post CPB, low cardiac 
index in 24 hours, and poor psychomotor development index score after a year as 
compared to the high haematocrit group (30%). In  the same study there were no 
differences between patient in the low haematocrit (25%)  and high haematocrit 
(35%) (29).  
A randomised trial in stable critically ill intensive care unit paediatric patient showed a 
decreased transfusion rate in the restricted haemoglobin group (7 g/dL) as compared 
to the liberal group (9,5 g/dL), and there were no difference in outcomes (32). Other 
prospective, postoperative randomised controlled trials in the paediatric patient 
showed that restrictive haemoglobin trigger strategies for the cyanotic patient 9 g/dL 
(33) and the acyanotic 8 g/dL (34) can be tolerated. The acyanotic patients in the 
restrictive group had a decreased length of hospital stay as compared to the liberal 
counterpart with a haemoglobin aimed above 10 g/dL (34) .  
Decreasing the haemoglobin transfusion trigger can result in a decrease of cost per 
patient as less blood products are transfused (34). Avoiding transfusion of blood 
products will reduce the risk of developing transfusion related adverse effects.  
Assessing the appropriate use of blood product transfusion is important as it monitors 
the utilisation practices of an institution. A study by Wade et al (3) on 85 paediatric 
patients at a tertiary institution showed an inappropriate use of fresh frozen plasma of 
58% (18/41 transfusion episodes) and an appropriate overall blood product 
transfusion of 83% (153/184 transfusion episodes), but there is no study identified 
assessing appropriateness in the paediatric cardiac patient.  
A retrospective audit of anaesthetic and trauma data merged with the blood bank 
database on red packed cells unit transfusion was done by Keung et al (2)  in a 
children’s hospital. This audit showed that in a two-year period 9838 units of red 
blood cells where issued in the hospital by the blood bank. Fourty-one percent of the 
total units were transfused perioperatively, and also indicated that cardiac surgery 
was the department with the largest number of units transfused, 1663 units. This 
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study shows that blood products are used markedly so in cardiac surgery, hence the 
need to assess blood product usage in our setting.  
Problem statement 
Although blood transfusion is associated with many benefits (8), there is an 
associated increase in morbidity with the transfusion of blood products in paediatric 
cardiac surgery on CPB (4, 12, 13). Blood conservation strategies have been 
implemented to reduce blood product transfusion in paediatric cardiac surgery. No 
specific guidelines for transfusion of blood products during cardiac surgery on CPB in 
this patient population could be identified. 
Blood products are an expensive and scarce resource and should therefore be 
transfused only when absolutely necessary (7). The utilisation of blood products in 
paediatric cardiac surgery on CPB for congenital cardiac disease at Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) has not previously been audited. 
Aim 
The current study aims is to describe the utilisation of blood products in paediatric 
patients with congenital cardiac disease presenting for cardiac surgery on CPB at 
CMJAH. 
Objectives 
The primary objectives of this study are to: 
• describe the preoperative platelet count 
• describe the preoperative and intraoperative anticoagulant therapy (drug and 
dose)  
• describe the patient’s haemoglobin before, during, and after CPB 
• describe the type and volume of fluid administered to prime the CPB machine 
• describe the types and number of blood products transfused intraoperatively 
by the anaesthetist 
• describe the type and number of blood product units transfused on CPB by the 
perfusionist 
• describe strategies used to minimise blood transfusion during CPB. 
The secondary objectives are:  
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• to analyse the blood products transfused according to RACHS categories and 
weight categories 
• to describe the association between blood products transfused and CPB and 
aortic cross-clamp times. 
Research assumptions 
The definitions that will be used in this study are as follows: 
Paediatric patients: will include the neonate, infant and child. 
Neonate: is a child from birth until one month. 
Infant: child older than one month but less than a year. 
Child: older than one year but less than 18 years. 
Patient records: in this study will include patient file, anaesthetic, perfusionist, and 
ICU charts and will be referred to collectively as records. 
Demarcation of study field 
The current study is conducted in the theatre complex of CMJAH affiliated to the 
Department of Anaesthesiology at the University of the Witwatersrand.  CMJAH is a 
1200 bed central hospital. The hospital has 23 theatres of which two are for cardio 
thoracic surgery. On average 170 paediatric cardiac surgeries are done annually.  
Ethical considerations 
Approval to conduct the study will be obtained from the Human Research Ethics 
Committee (Medical) and the Postgraduate Committee of the University of the 
Witwatersrand. Permission will be requested from the CEO of CMJAH (Appendix A) 
to conduct the study. Permission will be requested from Head of Paediatric Cardio 
Thoracic Surgery (Appendix B) to access the perfusionists’ records and patient ICU 
records, and the Head of Anaesthesiology to access the anaesthetic records 
(Appendix C). 
This study is a retrospective study and no consent will be requested from the 
patients. The study will ensure anonymity by not having the patient’s name recorded 
while collecting data. The list of patients included in the study will be generated, and 
each patient will be allocated a study number and this will be used on the data 
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collection sheet. The list of patient name will be kept separate from the data 
collection sheet. Confidentiality will be maintained as only the researcher and 
supervisors will have access to the raw data. Data will be kept securely for six years 
after completion of the study. 
The current study will be conducted according to the principles of the Declaration of 
Helsinki (35) and the South African Guidelines for Good Clinical Practice (36). 
Research methodology 
Research design 
A retrospective, contextual, descriptive research design will be followed in this study. 
Retrospective is defined as “a dependent variable identified in the present and an 
attempt is made to determine the independent variable that occurred in the past” 
(37). In this study the blood transfusion practices from 2014 will be audited. 
A contextual study is focused on a specific group in a specific location (38). This 
study is contextual as it audits records of paediatric cardiac surgery patients, with 
congenital cardiac diseases, on CPB at CMJAH. 
A descriptive study is one in which “ phenomenon are described, or the relationship 
between variables is examined; no attempt is made to determine cause-effect 
relationships.” (37) This is a descriptive study as the blood product usage in 
paediatric cardiac surgery patients on CPB will be described.  
Study population 
The study population will consist of records of paediatric patients who underwent 
cardiac surgery for congenital cardiac disease on CPB at CMJAH. 
Study sample 
Sample method 
In this study a consecutive, convenience sampling method will be utilised. 
Consecutive sampling according to Endacott et al (39) is “a version of convenience 
sampling where every available individual or event within an accessible population is 
chosen.” They further state that this is “the best choice of non-random sampling”  
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Convenience sampling is a sampling process which includes subjects in the study by 
chance, because they happen to be “in the right place at the right time” (38). This 
study will access records of all children who underwent surgery for congenital cardiac 
disease on CPB during 2014. 
Sample size 
The sample size will be realised by the number of paediatric patients who underwent 
cardiac surgery on CPB for congenital heart disease from 1 January to 31 December 
2014. 
Inclusion and exclusion criteria 
The inclusion criteria for this study will be: 
• records of all paediatric patients who underwent cardiac surgery on CPB for 
congenital heart disease during the study period  
• legible records. 
The exclusion criteria for this study will be: 
• records of Jehovah’s Witness patients 
• missing or illegible records. 
Collection of data 
Once all the relevant permissions have been granted the researcher will review the 
records and exclude those that do not meet the eligibility criteria. The researcher will 
assign study numbers to all patient records that will be included in the study. 
The collected data will be logged onto a Microsoft ® Excel spreadsheet (Appendix 
D). The following data will be collected: 
• demographics ( age, gender, weight, type of congenital lesion, CPB time, 
aortic cross-clamp time, resternotomy operations) 
• preoperative anticoagulant therapy 
• preoperative platelet count 
•  perioperative haemoglobin ( before CPB, during CPB, after CPB) 
• priming CPB machine (type and volume of fluid, anticoagulants) 
• type and volume of blood product transfused intraoperatively by anaesthetist 
• type and volume of blood product administered by perfusionist 
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• strategies to minimise blood transfusion (cell saver, miniature CPB, 
ultrafiltration, autologous blood transfusion, antifibrinolytic agents) 
• other. 
Data analysis 
A biostatistician will assist with the analysis of data using Stata ®14. Data will be 
analysed using descriptive and inferential statistics. Frequencies and percentages 
will be used to describe categorical variables, means and standard deviations, or 
medians and interquartile ranges will be used to describe the continuous variables 
depending on the distribution of the data. The Kruskal-Wallis or One-way Anova 
analysis of variance will be conducted to determine the median or mean differences 
of clinical variables respectively. A p value equivalent to or under 0.05 will be 
considered significant. 
Significance of the study  
One of the objectives of the World Health Organisation is to encourage the 
appropriate utilisation of blood products, hence the introduction of a haemovigilance 
programme which is also practiced by the South Africa National Blood Service (40). 
This study will describe whether the transfusion practices at CMJAH are comparable 
with what is practiced in other institutions and if there are any blood conservation 
strategies used. 
The results from this study will draw attention to the blood transfusion practices in 
paediatric cardiac surgery patients on CPB at CMJAH and will indicate if a change of 
practice is necessary to ensure improved use of blood products. The results may 
further contribute to the development of transfusion protocols for this group of 
patients in the future. 
Validity and reliability of the study 
Research should always have validity and reliability and these should be considered 
while formulating the study design. “Validity indicates whether the conclusions of the 
study are justified based on the design and interpretation” and it also “refers to the 
degree to which a measurement represents a true value.” “Reliability represents the 
consistency of the measure achieved” (41). 
• The validity and reliability of this study will be ensured by: 
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• using an applicable study design 
• data being collected by one researcher  
• recording data on a standardised spreadsheet 
• checking every 10th data entry point 
• analysis of data being done in conjunction with a biostatistician. 
Potential limitations of the study 
The current study depends on data collected from records completed by 
anaesthetists and perfusionists. Records may be missing, incomplete or illegible 
resulting in patient exclusion from the study.  
This study will be done contextually at CMJAH and the findings may not be 
generalised to other paediatric patients with congenital heart disease undergoing 
cardiac surgery on CPB. 
Project outline 
Month May-
June 
2015 
July 
2015 
Aug. -
Oct. 
2015 
Nov.- 
Dec. 
2015 
Jan. 
2016 
Feb.-
Mar. 
2016 
April 
2016 
May 
2016 
Literature 
review and 
proposal 
X        
Proposal 
submission  
X X       
Permission 
granted 
  X      
Data 
collection 
   X X    
Data 
analysis   
     X   
Article  
      X  
Submit  
       X 
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Financial plan 
The Department of Anaesthesiology will bear the cost of printing and paper. 
Description  Price per item Amount of items Total 
Printing   R1 per page 800 R800 
Ring binding for 
examination 
submission 
R50  2 R100 
Binding of final 
research report 
R200 2 R400 
Total   R1300 
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Appendices 
Appendices A: Letter to CEO of CMJAH 
858 Quail street 
Helderkruin, 1726 
24 June 2016 
CEO CMJAH 
Private Bag X39, Parktown 
Johannesburg,2193 
RE: Permission to conduct an audit of blood product transfusion practices on 
paediatric patients who underwent cardiac surgery on CPB. 
Dear Sir/Madam 
I am Caroline Tumelo Bayebaye a registrar in the Department of Anaesthesiology 
(WITS) currently doing my MMed research. I hereby request permission to conduct 
my study which is a retrospective audit of blood transfusion practices on paediatric 
patients who underwent congenital cardiac surgery in the year 2014 at CMJAH.  
Anonymity and confidentiality will be maintained in the study and there will be no cost 
to the hospital. 
The study has been approved by the Postgraduate Committee and the Human 
Research Ethics Committee (Medical). Please find these approvals attached.  
Regards 
Dr CT Bayebaye 
tumzaa@hotmail.com 
0723271758  
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Appendix B: Letter to Head of Paediatric Cardiothoracic Surgery 
858 Quail street  
Helderkruin, 1726 
         24 June 2015 
Private Bag X39, Parktown 
Johannesburg, 2193        
RE: Permission to access perfusionists’ and ICU records  
Dear Dr Cathy Van der Donck 
My name is Caroline Tumelo Bayebaye registrar in the Department of 
Anaesthesiology (WITS) currently doing my MMed research. My MMed is a 
retrospective audit of blood product transfusion practices on the paediatric patients 
who underwent congenital heart surgery on cardiopulmonary bypass from 01 
January 2014 to 31 December 2014.  
The aim of the study is to describe transfusion practices in the unit and compare 
them to what is done in other institutions. 
I am requesting permission to conduct the study and also to have access to patient 
ICU and perfusionists’ records. The records will be reviewed on the premises and the 
identity of patients and clinicians will not be included in the study. 
The research will be conducted after approval by the Postgraduate Committee and 
the Human Research Ethics Committee (Medical). 
Regards 
Dr CT Bayebaye (0723271758)  
tumzaa@hotmail.com 
  
71 
 
Appendix C: Letter to Head of Anaesthesiology at CMJAH 
858 Quail street 
Helderkruin, 1726 
24 June 2014 
Head of Anaesthesiology CMJAH 
Private Bag X39, Parktown 
Johannesburg, 2193 
RE: Permission to access anaesthetic charts 
Dear Prof Oosthuizen 
My name is Caroline Tumelo Bayebaye, a registrar in the Department of 
Anaesthesiology (WITS). I am currently busy with my MMed research which is an 
audit of blood product transfusion in paediatric patients who underwent congenital 
heart disease surgery on bypass from 01 January to 31 December 2014. 
I am requesting permission to be able to access the anaesthetic charts to proceed 
with my study. Patient and clinician identity will not be included in the study and the 
charts will be reviewed on the premises. 
The research will be conducted after approval by the Postgraduate Committee and 
the Human Research Ethics Committee (Medical). 
Regards 
CT Bayebaye 
tumzaa@hotmail.com 
0723271758   
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Appendix D: Example of data to be collected on spreadsheet 
Participant number 1 2 3 4 5 6 
Demographics        
Age       
Gender       
Weight       
Cardiac lesion       
Aortic cross clamp time       
CBP time       
Resternotomy operations       
Preoperative anticoagulant       
Platelets preoperative       
CPB prime       
Fluid type       
Volume (ml)       
Anticoagulant        
HB       
Before CPB       
During CPB       
After CPB       
Anaesthetist blood product 
volume (ml) 
      
RBC       
FFP       
Platelet       
Cryoprecipitate       
Perfusionist blood product 
volume (ml) 
      
RPC       
FFP       
Platelet       
Cryoprecipitate       
Blood conservation strategies       
Cell saver       
Autologous transfusion       
Miniature CPB       
Antifibrinolytic agent       
Ultrafiltration       
Other        
 
 
 
